United States

Cerus Corp (CERS.O)

CERS.O on Consolidated Issue listed on NASDAQ Global Market

24 Jan 2017
Change (% chg)

$0.01 (+0.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CERS.O


Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)


Beta: 2.07
Market Cap(Mil.): $434.56
Shares Outstanding(Mil.): 103.47
Dividend: --
Yield (%): --


  CERS.O Industry Sector
P/E (TTM): -- 32.91 29.85
EPS (TTM): -0.64 -- --
ROI: -61.54 13.14 14.85
ROE: -76.46 16.77 16.28

BRIEF-Cerus Corp reports Q3 loss per share $0.14

* Continues to expect 2016 global product revenue in range of $37 million to $40 million

Nov 03 2016

BRIEF-Cerus announces first U.S. Blood center customer submits biologics license application

* Cerus announces first U.S. Blood center customer submits biologics license application to the FDA to allow for interstate export of intercept platelet components

Oct 13 2016

BRIEF-FDA recommends use of pathogen reduction for universal Zika risk reduction of blood components

* Fda's new recommendation for universal zika risk reduction of blood components includes use of pathogen reduction

Aug 29 2016

BRIEF-Cerus Q2 loss per share $0.18

* Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

Aug 04 2016

UPDATE 1-FDA takes steps to protect blood supply in Florida amid Zika probe

CHICAGO, July 28 The U.S. Food and Drug Administration has ordered blood banks in Florida's two most densely populated counties to stop collecting blood as health officials determine whether Zika has begun transmission in the continental United States.

Jul 28 2016


  Price Chg
Terumo Corp (4543.T) ¥4,155 --
Grifols SA (GRLS.MC) €19.26 -0.04
Grifols SA (GRLSbn.MC) €15.66 -0.07

Earnings vs. Estimates